ESR2 and neoplasm: Finally, emerging evidence for the tumor suppressive functions of ERβ in many cancers like breast [6], colon [7], ovarian [8] and prostate [9] cancer make the ERβ selective agonists promising drugs for the future treatment of these tumors.